Medigene AG: Medigene AG to participate at upcoming conferences

Planegg/Martinsried (pta013/02.11.2023/11:00 UTC+1)

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the 29th Annual BIO-Europe taking place November 6-8, 2023, in Munich and present at the Deutsches Eigenkapitalforum to be held November 27-29, 2023, in Frankfurt.

BIO-Europe 2023

https://informaconnect.com/bioeurope/

Date: November 6-8, 2023

Location: Trade Fair Center Messe München

Members of Medigene's Corporate Development team will be available for one-on-one meetings at the event.

Corporate presentation – Deutsches Eigenkapitalforum 2023

https://www.eigenkapitalforum.com/de/

Date and time: Monday, November 27, 2023, 2:05 pm – 2:35 pm (local time), conference room London

Location: Steigenberger Airport Hotel Frankfurt

Members of Medigene's management team will be available for one-on-one meetings at the event.

Please contact Julia von Hummel of MC Services at Julia.vonHummel@mc-services.eu to schedule a meeting at either one of the conferences.

--- end of press release ---

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its End-to-End Platform, built on multiple proprietary and exclusive TCR generation and optimization, as well as product enhancement technologies, allows Medigene to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for safety, efficacy and durability. For more information, please visit: www.medigene.com

Medigene

Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.com
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate